For millions of patients with atrial fibrillation, the standard procedure to restore a normal heart rhythm is a controlled, painful electric shock. It is a necessary jolt, but one that often requires sedation and carries a significant psychological burden. MediCool Technologies, a medical device spinout from the Mayo Clinic, is betting there is a better way: an implantable device that cools the heart tissue instead of shocking it, a concept its founders call Cool Cardioversion [MediCool Technologies, Feb 2026].
A clinical bet on thermal cooling
MediCool's core technology is a hardware pivot. Instead of delivering a high-energy electrical pulse, the company's implantable device uses thermal cooling to terminate dangerous arrhythmias like atrial fibrillation (AFib) [Michigan Rise, May 2023]. The initial target is post-operative AFib, a common and costly complication after major heart surgery. The company's scientific foundation is rooted in the work of its founders, cardiac electrophysiologists Dr. Paul Friedman and Dr. Sam Asirvatham, who began the research at the Mayo Clinic in 2015 [MediCool Technologies, Jul 2026]. The company has progressed to first-in-human data, published in the peer-reviewed journal Heart Rhythm O2, and is now preparing for a U.S. Early Feasibility Study slated for 2026 [MediCool Technologies, Jul 2026]. This regulatory pathway is a critical step for any novel implantable device seeking FDA clearance.
The team and the capital behind the science
The leadership team reflects a blend of deep clinical expertise and seasoned device industry experience. Dr. Friedman serves as Chief Technology Officer, while Dr. Asirvatham is Chief Medical Officer, anchoring the company's scientific and clinical strategy. Jeff Rynbrandt, a veteran of the medical device sector, leads as CEO, with Rich Sanders, who has a background in medtech executive roles, serving as Executive Chairman [MediCool Technologies, Jul 2026]. This structure suggests a deliberate focus on translating academic research into a viable commercial product. Funding has followed a classic, capital-efficient biotech trajectory, with early support from the National Science Foundation's SBIR grants for preclinical work, followed by a seed round of approximately $3 million from investors including Mayo Clinic Ventures and Michigan Rise [PitchBook].
| Role | Name | Background |
|---|---|---|
| CEO & Director | Jeff Rynbrandt | Medical device industry veteran |
| CTO & Director | Dr. Paul Friedman | Mayo Clinic cardiac electrophysiologist, co-founder |
| CMO & Director | Dr. Sam Asirvatham | Mayo Clinic cardiac electrophysiologist, co-founder |
| Executive Chairman | Rich Sanders | Medical technology executive |
Where the clinical road gets steep
The ambition is clear, but the path is lined with the formidable challenges inherent to any new implantable cardiac device. The company's total disclosed funding of roughly $3 million is modest for the clinical and regulatory marathon ahead, which includes the planned Early Feasibility Study and any subsequent pivotal trials required for market approval. While the first-in-human data is a positive signal, it represents an early proof of concept; larger, controlled studies will be needed to demonstrate consistent safety and efficacy to the satisfaction of regulators and clinicians. Furthermore, MediCool is proposing a fundamental shift in a well-established treatment paradigm. Cardiologists are deeply familiar with the mechanics and outcomes of electrical cardioversion. Convincing them to adopt a novel, cooling-based technology will require not just regulatory approval, but compelling clinical data that shows clear patient benefit over the current standard.
The company's near-term milestones will be telling. Success in the 2026 Early Feasibility Study would provide crucial human safety data and likely attract further investment to fuel larger trials. A stumble, however, could stall momentum in a field where clinical validation is the only currency that matters.
For patients living with atrial fibrillation, the current standard of care is a spectrum of options, each with trade-offs. Pharmacological management with anti-arrhythmic drugs is common but can have systemic side effects and variable efficacy. When drugs fail or are unsuitable, electrical cardioversion is the go-to procedure. It is effective, but the experience of a deliberate, painful shock to the chest,often requiring anesthesia,is a significant deterrent that can lead patients to delay necessary treatment. For a subset of patients, more invasive catheter ablation procedures are an option. MediCool's bet is that a painless, implantable alternative could not only improve the patient experience but also encourage earlier intervention, potentially reducing long-term complications like stroke. The next few years of clinical work will determine if cooling the heart can truly become a warmer prospect for patients.
Sources
- [MediCool Technologies, Feb 2026] MediCool Technologies - Painless therapy to terminate dangerous cardiac arrhythmias | https://medicooltech.com/
- [Michigan Rise, May 2023] Michigan Rise Supports Development of Therapy for Atrial Fibrillation (A-Fib) with Investment in MediCool Technologies | https://michiganrise.com/2023/05/15/michigan-rise-supports-development-of-therapy-for-atrial-fibrillation-a-fib-with-investment-in-medicool-technologies/
- [MediCool Technologies, Jul 2026] History | https://medicooltech.com/history/
- [MediCool Technologies, Jul 2026] Team | https://medicooltech.com/team/
- [PitchBook] MediCool Technologies funding profile | https://pitchbook.com/profiles/company/233566-93